Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034348825> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2034348825 endingPage "1565" @default.
- W2034348825 startingPage "1561" @default.
- W2034348825 abstract "Continuous i.v. epoprostenol (prostacyclin) therapy improves survival and quality of life in patients with pulmonary arterial hypertension (PAH). i.v. epoprostenol therapy may be limited by serious complications related to the need for an implanted central venous catheter, and its chemical instability and short half-life. Treprostinil is a longer-acting prostacyclin analog, chemically stable, and suitable for continuous subcutaneous administration. We report successful transitioning to subcutaneous treprostinil of patients who presented with life-threatening complications of i.v. epoprostenol delivery.Open, uncontrolled study.ICUs and departments of cardiology at academic hospitals.Eight patients with PAH treated with continuous i.v. epoprostenol.Transition to subcutaneous treprostinil following an empiric protocol.Transition to treprostinil was achieved successfully in 21 to 96 h, with no major adverse side effects, and no change in the improved clinical status achieved with i.v. epoprostenol. Doses of epoprostenol before transition ranged from 3.5 to 75 ng/kg/min (mean, 27 ng/kg/min). Doses of treprostinil at completion of the transition ranged from 3 to 65 ng/kg/min (mean, 22 ng/kg/min). Four to 11 months later, the patients remained clinically improved. In spite of mild-to-moderate infusion site pain, all patients reported an improved sense of comfort and well-being.Patients with PAH can be safely transitioned from treatment with i.v. epoprostenol to subcutaneous treprostinil." @default.
- W2034348825 created "2016-06-24" @default.
- W2034348825 creator A5018972286 @default.
- W2034348825 creator A5041984682 @default.
- W2034348825 creator A5055104644 @default.
- W2034348825 creator A5067984012 @default.
- W2034348825 creator A5070323256 @default.
- W2034348825 creator A5090166540 @default.
- W2034348825 date "2002-05-01" @default.
- W2034348825 modified "2023-10-16" @default.
- W2034348825 title "Transitioning From IV Epoprostenol to Subcutaneous Treprostinil in Pulmonary Arterial Hypertension" @default.
- W2034348825 cites W1979969712 @default.
- W2034348825 cites W2017583311 @default.
- W2034348825 cites W2037502378 @default.
- W2034348825 cites W2041151644 @default.
- W2034348825 cites W2044919495 @default.
- W2034348825 cites W2062296681 @default.
- W2034348825 cites W2070485900 @default.
- W2034348825 cites W2131897774 @default.
- W2034348825 cites W2135510321 @default.
- W2034348825 cites W2142104554 @default.
- W2034348825 cites W2161347639 @default.
- W2034348825 cites W2321522617 @default.
- W2034348825 doi "https://doi.org/10.1378/chest.121.5.1561" @default.
- W2034348825 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12006444" @default.
- W2034348825 hasPublicationYear "2002" @default.
- W2034348825 type Work @default.
- W2034348825 sameAs 2034348825 @default.
- W2034348825 citedByCount "106" @default.
- W2034348825 countsByYear W20343488252012 @default.
- W2034348825 countsByYear W20343488252013 @default.
- W2034348825 countsByYear W20343488252014 @default.
- W2034348825 countsByYear W20343488252015 @default.
- W2034348825 countsByYear W20343488252016 @default.
- W2034348825 countsByYear W20343488252017 @default.
- W2034348825 countsByYear W20343488252018 @default.
- W2034348825 countsByYear W20343488252019 @default.
- W2034348825 countsByYear W20343488252020 @default.
- W2034348825 countsByYear W20343488252021 @default.
- W2034348825 countsByYear W20343488252022 @default.
- W2034348825 countsByYear W20343488252023 @default.
- W2034348825 crossrefType "journal-article" @default.
- W2034348825 hasAuthorship W2034348825A5018972286 @default.
- W2034348825 hasAuthorship W2034348825A5041984682 @default.
- W2034348825 hasAuthorship W2034348825A5055104644 @default.
- W2034348825 hasAuthorship W2034348825A5067984012 @default.
- W2034348825 hasAuthorship W2034348825A5070323256 @default.
- W2034348825 hasAuthorship W2034348825A5090166540 @default.
- W2034348825 hasConcept C126322002 @default.
- W2034348825 hasConcept C141071460 @default.
- W2034348825 hasConcept C197934379 @default.
- W2034348825 hasConcept C2776432619 @default.
- W2034348825 hasConcept C2780930700 @default.
- W2034348825 hasConcept C2781128415 @default.
- W2034348825 hasConcept C42219234 @default.
- W2034348825 hasConcept C71924100 @default.
- W2034348825 hasConceptScore W2034348825C126322002 @default.
- W2034348825 hasConceptScore W2034348825C141071460 @default.
- W2034348825 hasConceptScore W2034348825C197934379 @default.
- W2034348825 hasConceptScore W2034348825C2776432619 @default.
- W2034348825 hasConceptScore W2034348825C2780930700 @default.
- W2034348825 hasConceptScore W2034348825C2781128415 @default.
- W2034348825 hasConceptScore W2034348825C42219234 @default.
- W2034348825 hasConceptScore W2034348825C71924100 @default.
- W2034348825 hasIssue "5" @default.
- W2034348825 hasLocation W20343488251 @default.
- W2034348825 hasLocation W20343488252 @default.
- W2034348825 hasOpenAccess W2034348825 @default.
- W2034348825 hasPrimaryLocation W20343488251 @default.
- W2034348825 hasRelatedWork W1484930646 @default.
- W2034348825 hasRelatedWork W1945023983 @default.
- W2034348825 hasRelatedWork W1995044472 @default.
- W2034348825 hasRelatedWork W2055503826 @default.
- W2034348825 hasRelatedWork W2077952441 @default.
- W2034348825 hasRelatedWork W2093673373 @default.
- W2034348825 hasRelatedWork W2412876171 @default.
- W2034348825 hasRelatedWork W2790230897 @default.
- W2034348825 hasRelatedWork W4387065406 @default.
- W2034348825 hasRelatedWork W2079421967 @default.
- W2034348825 hasVolume "121" @default.
- W2034348825 isParatext "false" @default.
- W2034348825 isRetracted "false" @default.
- W2034348825 magId "2034348825" @default.
- W2034348825 workType "article" @default.